Skip to content Home / Companies / ANTX ANT
AN2 Therapeutics, Inc. (ANTX) XNAS PHARMACEUTICAL PREPARATIONS Net insider selling (90d) Watch ANTX
Latest ANTX Insider Trades
About AN2 Therapeutics, Inc. (ANTX) AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
Headquarters MENLO PARK, CA
Employees 21
Listed 2022
Exchange XNAS https://www.an2therapeutics.com SEC filings for ANTX on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 4 41,612 $239K Grant or award 3 6,407 Bona-fide gift 1 405,880
ANTX Insider Transactions (Form 4) 89 64 Form 4 filings on record, the earliest from Nov 5, 2024, newest first. Filing history page 1 of 3.
Date Insider Transaction Security Shares Price Value Aug 17, 2026 RR Robin Shane Readnour - Director Open-market sale Common Stock 16,696
Recent ANTX Form 8-K Filings 5
Recent ANTX Form 144 Notices of Proposed Sale 1 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 17, 2026 Readnour Robin Shane Director 1,012,000 $6.08M View on EDGAR
ANTX Insider Trading - FAQ
What is the latest insider trade for ANTX? AN2 Therapeutics, Inc. (ANTX) had 7 insider filings in the last 90 days, with the most recent on 2026-08-19. The full record for ANTX runs to 64 Form 4 filings, the earliest from 2024-11-05. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying ANTX stock? No insider purchases of ANTX were filed in the last 90 days. 18 purchases are on record for this company.
How many insiders are selling ANTX stock? 4 insider sales of ANTX were filed in the last 90 days, totaling $239K.
Where can I see ANTX SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks ANTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow ANTX insider buys? Create a free InsiderAlpha account and press Watch on this page to add ANTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track ANTX insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free - Officer
Market cap $210.57M
P/E ratio -
Dividend yield -
Average volume 282.2K
52 week high $7.19
52 week low $1.00
Today's high $5.78
Today's low $5.40
Open $5.67
Volume 240.9K
Previous close $5.74
Shares outstanding 37.74M Market cap
$210.57M
21 employees
ANTX Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 4 sales totaling $239K.
Most-Active ANTX Insiders - Last 90 Days 10 Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Jul 10, 2026 KA Kabeer Aziz Grant or award Common Stock 2,852 $0.00 -
Jul 8, 2026 JE Joshua M. Eizen - Officer Open-market sale Common Stock 5,945 $4.17 $25K
Apr 10, 2026 KA Kabeer Aziz Grant or award Common Stock 3,775 $0.00 -
Mar 19, 2026 LD Lucy Day - Officer Grant or award Stock Option (right to buy) 73,665 - -
Mar 19, 2026 LD Lucy Day - Officer Derivative Stock Option (right to buy) 73,665 - -
Mar 19, 2026 LD Lucy Day - Officer Grant or award Stock Option (right to buy) 66,000 - -
Mar 19, 2026 LD Lucy Day - Officer Derivative Stock Option (right to buy) 66,000 - -
Mar 19, 2026 LD Lucy Day - Officer Grant or award Stock Option (right to buy) 82,300 - -
Mar 19, 2026 LD Lucy Day - Officer Derivative Stock Option (right to buy) 82,300 - -
Mar 19, 2026 SC Sanjay Chanda - Officer Grant or award Stock Option (right to buy) 66,000 - -
Mar 19, 2026 SC Sanjay Chanda - Officer Derivative Stock Option (right to buy) 66,000 - -
Mar 19, 2026 SC Sanjay Chanda - Officer Grant or award Stock Option (right to buy) 57,950 - -
Mar 19, 2026 SC Sanjay Chanda - Officer Derivative Stock Option (right to buy) 57,950 - -
Mar 19, 2026 SC Sanjay Chanda - Officer Grant or award Stock Option (right to buy) 41,665 - -
Mar 19, 2026 SC Sanjay Chanda - Officer Derivative Stock Option (right to buy) 41,665 - -
Mar 19, 2026 KA Kabeer Aziz Grant or award Stock Option (right to buy) 20,724 - -
Mar 19, 2026 KA Kabeer Aziz Derivative Stock Option (right to buy) 20,724 - -
Mar 19, 2026 KA Kabeer Aziz Grant or award Stock Option (right to buy) 23,742 - -
Mar 19, 2026 KA Kabeer Aziz Derivative Stock Option (right to buy) 23,742 - -
Mar 19, 2026 SW Stephanie Wong Grant or award Stock Option (right to buy) 24,999 - -
Mar 19, 2026 SW Stephanie Wong Derivative Stock Option (right to buy) 24,999 - -
Mar 19, 2026 SW Stephanie Wong Grant or award Stock Option (right to buy) 10,362 - -
Mar 19, 2026 SW Stephanie Wong Derivative Stock Option (right to buy) 10,362 - -
Mar 19, 2026 SW Stephanie Wong Grant or award Stock Option (right to buy) 23,742 - -
Mar 19, 2026 SW Stephanie Wong Derivative Stock Option (right to buy) 23,742 - -
Mar 19, 2026 JE Joshua M. Eizen - Officer Grant or award Stock Option (right to buy) 92,000 - -
Mar 19, 2026 JE Joshua M. Eizen - Officer Derivative Stock Option (right to buy) 92,000 - -
Mar 19, 2026 JE Joshua M. Eizen - Officer Grant or award Stock Option (right to buy) 50,150 - -
Mar 19, 2026 JE Joshua M. Eizen - Officer Derivative Stock Option (right to buy) 50,150 - -
Mar 19, 2026 EE Eric Easom - Officer Grant or award Stock Option (right to buy) 249,999 - -
Mar 19, 2026 EE Eric Easom - Officer Derivative Stock Option (right to buy) 249,999 - -
Mar 19, 2026 EE Eric Easom - Officer Grant or award Stock Option (right to buy) 225,000 - -
Mar 19, 2026 EE Eric Easom - Officer Derivative Stock Option (right to buy) 225,000 - -
Mar 19, 2026 EE Eric Easom - Officer Grant or award Stock Option (right to buy) 267,650 - -
Mar 19, 2026 EE Eric Easom - Officer Derivative Stock Option (right to buy) 267,650 - -
Feb 20, 2026 JE Joshua M. Eizen - Officer Grant or award Common Stock 50,000 $0.00 -
Feb 20, 2026 JE Joshua M. Eizen - Officer Grant or award Stock Option (right to buy) 100,000 $0.00 -
Feb 20, 2026 LD Lucy Day - Officer Grant or award Common Stock 38,000 $0.00 -
Feb 20, 2026 LD Lucy Day - Officer Grant or award Stock Option (right to buy) 77,000 $0.00 -
Feb 20, 2026 EE Eric Easom - Officer Grant or award Common Stock 112,250 $0.00 -
Feb 20, 2026 EE Eric Easom - Officer Grant or award Stock Option (right to buy) 224,500 $0.00 -
Feb 20, 2026 SC Sanjay Chanda - Officer Grant or award Common Stock 38,000 $0.00 -
Feb 20, 2026 SC Sanjay Chanda - Officer Grant or award Stock Option (right to buy) 77,000 $0.00 -
$IONS
IONIS PHARMACEUTICALS INC